Ataxia Telangiectasia (Louis-Bar syndrome)
Ataxia Telangiectasia (OMIM # 208900) or Louis-Bar syndrome ICD-9 334.8
Are You Confident of the Diagnosis?
What you should be alert for in the history
Patients generally present with neurologic impairment; ie, ataxia, since the first months of life. Truncal ataxia (oscillations of the trunk) may be evident at the 5th-6th months of life, while gait ataxia appears when the affected child starts to walk, with frequent falls. Oculomotor apraxia (slow or absent voluntary eye movements) is evident from the second year of life. Neurodegeneration is progressive, leading the patients to a wheelchair in the second decade of life (
Representation of the first hallmark of this entity (ataxia) that can occur even within the first year of life.
Many patients (around 70%) suffer recurrent sinopulmonary infections, leading most of them to death in the teens. The second cause of death is the occurrence of T-cell leukemia or lymphoma or, more rarely, solid tumors. The dramatic radiohypersensitivity associated with this disease makes antitumoral treatments difficult, so that attenuated protocols are generally used.
Characteristic findings on physical examination
The second hallmark of the disease is the presence of oculocutaneous telangiectasias (
Expected results of diagnostic studies
The diagnosis is supported by high levels of serum alfafetoprotein and an increased rate of chromosomal breakage, both spontaneous and induced by gamma radiations and radiomimetic drugs, and by the absence of ATM protein (as shown by Western Blot analysis). Nuclear magnetic resonance imaging (NMR) demonstrates a nonspecific cerebellar atrophy, involving the vermis and/or the hemispheres, and the enlargement of the fourth ventricle.
Confirmation of the diagnosis is sometimes difficult in patients with a milder phenotype; differential diagnosis compared with AT-LD (ataxia Telangiectasia-like disorder), AOA1 and AOA2 (ataxias with oculomotor apraxia type 1 and 2 (AOA1, AOA2) is primarily done in the laboratory on the basis of a multiple Western blots done with the specific antibodies. The molecular analysis of the ATM gene, performed by denaturing high-performance liquid chromatography (DHPLC), direct sequencing and/or multiplex ligation-dependent probe assay (MLPA), gives the definitive confirmation of the diagnosis.
Who is at Risk for Developing this Disease?
Ataxia Telangiectasia is inherited in autosomal recessive manner, which means that two healthy parents, both carriers of one ATM mutation, have at each pregnancy a 25% risk of giving birth to an affected child. As is the case other autosomal recessive diseases, consanguinity is a risk factor. Ataxia Telangiectasia is present worldwide.
What is the Cause of the Disease?
Ataxia telangiectasia is caused by biallelic mutations in the ATM gene
The ATM gene is a controller of the cell cycle and of the cellular response to oxidative stress and to DNA double strand breaks, the most toxic lesions of DNA. Absence of ATM protein leads to dysregulation of the cell cycle, no repair of DNA lesions, and an increased rate of chromosomal damage.
Systemic Implications and Complications
Ataxia Telangiectasia is a multisystemic disease with neurologic, immunologic and endocrine features. The most striking complication is the recurrence of sinopulmonary infections, due to immunodeficiency and /or difficulty in deglutition, causing aspiration (ab ingestis pneumoni). Periodic infusion of immunoglobulins and constant physiotherapeutic support could delay the consequences of these defects.
The prevention of the primary manifestations of the disease has been so far unsuccessful. Symptomatic therapies with minimum or null effects have been attempted in past years. Recently, few patients have been shown to be responsive to corticosteroid therapy. Therapeutic trials with beta- and dexa-methasone are now in progress to enlarge the number of the treated patients and to find the optimal dosage that could reduce the collateral effects of prolonged corticosteroid administration.
Optimal Therapeutic Approach for this Disease
Patients must constantly undergo physiotherapy, especially to relieve respiratory problems. Hyppotherapy is also fruitful, especially to ameliorate the ataxic posture. Wheelchairs are necessary by 10-12 years of age in patients with the classical, severe form of the disease.
Follow-up of patients is compulsory for both neurologic and immunologic problems. Nevertheless, due to the absence of an effective therapy, progressive cachexia is unstoppable. If malignancy is present, attenuated therapeutic protocols must be used.
Unusual Clinical Scenarios to Consider in Patient Management
In recent years, the number of patients diagnosed in adult age has increased, due to the refinement of diagnostic instruments. These patients have a late onset (at least after puberty) of neurologic features, starting generally with periferic involvement (hypotonia, tremors, chorea).
Ataxia becomes evident years after the onset and could remain mild for years, allowing a quite normal life and also reproduction. Considering the mild phenotype, a dosage of serum alfafetoprotein is in our opinion compulsory in all adult patients with idiopathic ataxia and negative molecular results with respect to the other forms of adult ataxia.
In classical patients, the amelioration of quality of life has in the last two decades prolonged lifespan; as a consequence , the number of AT patients suffering tumors is increasing and solid tumors (meningioma, breast and gastric carcinomas, etc) are frequently described. Oncologists must be careful aware in the treatment of these patients, using attenuated protocols as well as reducing the amount of radiological analyses.
What is the Evidence?
Broccoletti, T, Del Giudice, E, Cirillo, E, Giardino, G, Ginocchio, VM, Bruscoli, S. "Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia". Eur J Neurol. 2010 sep 14.(The aim of this study was to evaluate the minimum therapeutically effective dosage of betamethasone on neurological symptoms of AT in six responsive patients with AT. The authors found that betamethasone is effective in A-T at a minimal dosage and provide Class IIIA evidence that betamethasone at very low dosage is effective in improving neurologic signs of patients affected with ataxia telangiectasia.)
Buoni, S, Zannolli, R, Sorrentino, L, Fois, A. "Betamethasone and improvement of neurological signs in ataxia-telangiectasia patients". Arch Neurol. vol. 63. 2006. pp. 1479-82.(This is the first report on the control of central nervous system symptoms inpatients with ataxia-telangiectasia. It describes the effectiveness of corticosteroid therapy on the central nervous system symptoms of a child with ataxia-telangiectasia in whom neurologic signs improved when, occasionally, he was given betamethasone to treat asthmatic bronchitis attacks.)
Chun, HH, Gatti, RA. "Ataxia-telangiectasia, an evolving phenotype". DNA Repair. vol. 3. 2004. pp. 1187-96.(This review article describes elements of ataxia-telangiectasia, summarizes laboratory findings, and defines characteristics of the distinguished from other autosomal recessive cerebellar ataxias (ARCAs) such as Friedreich ataxia, Mre11 deficiency (AT-like disease), and the oculomotor apraxias 1 (aprataxin deficiency) and 2 (senataxin deficiency) on molecular testing.)
Drolet, BA, Drolet, B, Zvulunov, A, Jacobsen, R, Troy, J, Esterly, NB. "Cutaneous granulomas as a presenting sign in ataxia-telangiectasia". Dermatology. vol. 194. 1997. pp. 273-5.(Telangiectasia is the classic cutaneous finding of ataxia-telangiectasia (AT)and is often the physical finding that suggests the diagnosis. The authors report a patient in whom noninfectious cutaneous granulomas were the presenting cutaneous feature of AT and discuss immunodeficiency syndromes that are associated with similar cutaneous granulomas.)
Lavin, MF, Shiloh, Y. "The genetic defect in ataxia-telangiectasia". Ann Rev Immunol. vol. 15. 1997. pp. 177-202.This article is a detailed review of the genetic defect in ataxia telangiectasia and its role in he chromosomal instability and radiosensitivity so characteristic of this disease, emphasizing the insights into the nature of the defect provided by the recent identification, by positional cloning, of the responsible gene, ATM.)
Leuzzi, V, Elli, R, Antonelli, A, Chessa, L, Cardona, F, Marcucci, L, Petrinelli, P. "Neurological and cytogenetic studies in early-onset ataxia-telangiectasia patients". Eur J Pediatr. vol. 152. 1993. pp. 609-12.(The clinical diagnosis of AT is difficult before the age of 4 years. The authors report clinical and cytogenetic data on three early-onset, early-diagnosed AT patients at the age of 12, 18 and 22 months, respectively.)
Lewis, RF, Lederman, HM, Crawford, TO. "Ocular motor abnormalities in Ataxia Telangiectasia". Ann Neurol. vol. 46. 1999. pp. 287-95.(Although abnormal eye movements are a prominent feature of ataxia telangiectasia, the characteristics of the oculomotor dysfunction have been reported only in small groups of patients. The authors examined eye movements in 56 patients with ataxia telangiectasia, obtaining electrooculographic recordings of eye movements in 33 subjects.)
Louis-Bar, D. "Sur un syndrome progressif comprenant des télangiectasies capillaires cutanées et conjonctivales symmetriques naevoides et de troubles crerebellaux". Confin Neurol (Basel). vol. 4. 1941. pp. 432-42.(The first description of patients with AT was published by Syllaba and Henner in 1926. They reported three adolescent Czech siblings with progressive choreoathetosis and striking ocular telangiectasia as having a variant of Ramsay Hunt’s familial double athetosis. In 1941, a second clinical description was published by Louis-Bar, regarding a 9-year-old Belgian boy with progressive cerebellar ataxia and extensive cutaneous telangiectasia distributed in nevoid patches; neither family history nor pathologic studies were reported. The author identified the syndrome as a previously undescribed entity belonging among the phakomatoses, either a variant of the Sturge-Weber syndrome or a separate new entity.)
Savitsky, K, Bar-Shira, A, Gilad, S, Rotman, G, Ziv, Y, Vanagaite, L. "A single Ataxia Telangiectasia gene with a product similar to PI-3 kinase". Science. vol. 268. 1995. pp. 1749-53.(The ATM gene, which is mutated in the autosomal recessive disorder ataxia telangiectasia [AT], was identified by positional cloning on chromosome 11q22-23. The discovery of ATM enhanced understanding of AT and related syndromes and may allow the identification of AT heterozygotes, who are at increased risk of cancer.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Study Reveals Scope of Genomic Variation Within Cancer Cell Lines
- Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer